Gs signaling pathway distinguishes hallucinogenic and nonhallucinogenic 5-HT2AR agonists induced head twitch response in mice.

@article{Liu2022GsSP,
  title={Gs signaling pathway distinguishes hallucinogenic and nonhallucinogenic 5-HT2AR agonists induced head twitch response in mice.},
  author={Xiaoqian Liu and Huili Zhu and Huan Gao and X. Tian and Bowei Tan and Ruibin Su},
  journal={Biochemical and biophysical research communications},
  year={2022},
  volume={598},
  pages={
          20-25
        }
}
View on PubMed
doi.org

References

SHOWING 1-10 OF 22 REFERENCES
Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
Role of Gq protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
Differential signaling signatures evoked by DOI versus lisuride stimulation of the 5-HT2A receptor.
5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice
TLDR
Data indicate that the decrease in locomotor activity induced by 10 mg/kg DOI is mediated by 5-HT2C receptors, an interpretation that is supported by the finding that the selective 5- HT2C agonist WAY 161,503 produces reductions in the locomotory activity that are potentiated in 5HT2A KO mice.
Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT2A receptor activation
TLDR
The results suggest that in addition to the HTR, behavioral arrest and characteristic meso level slow waveforms are key hallmarks of the response to 5-HT 2A R activation.
The Chronic Treatment With 5-HT2A Receptor Agonists Affects the Behavior and the BDNF System in Mice.
TLDR
It is shown for the first time that the chronic activation of the 5-HT2A receptor with agonists has affected the BDNF system almost on all levels-transcription, proBDNF production, TrkB and p75NTR receptors' level.
A Non-Hallucinogenic Psychedelic Analog with Therapeutic Potential
TLDR
This work demonstrates that, through careful chemical design, it is possible to modify a psychedelic compound to produce a safer, non-hallucinogenic variant that has therapeutic potential.
Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades
Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice
...
...